| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
CASI Pharmaceuticals, Inc.
13D/A
Amendment 7
CASIF · G1933S101
|
4.8% |
1/20/2026
Event 9/30/2025
|
|||
| IDG-Accel China Growth Fund III L.P. | 4.5% | ||||
| IDG-Accel China III Investors L.P. | 4.5% | ||||
| IDG-Accel China Growth Fund III Associates L.P. | 4.5% | ||||
| IDG-Accel China Growth Fund GP III Associates Ltd. | 4.5% | ||||
| Ho Chi Sing | 4.5% | ||||
| Zhou Quan | 4.8% | ||||
|
Pony AI Inc.
13G
PONY · 732908108
|
4.3% |
11/12/2025
Event 9/30/2025
|
|||
| IDG China Venture Capital Fund IV L.P. | 4.3% | ||||
| IDG China IV Investors L.P. | 4.3% | ||||
| IDG China Capital Fund III L.P. | 4.3% | ||||
| IDG China Capital III Investors L.P. | 4.3% | ||||
| IDG China Venture Capital Fund IV Associates L.P. | 4.3% | ||||
| IDG China Venture Capital Fund GP IV Associates Ltd. | 4.3% | ||||
| IDG China Capital Fund III Associates L.P. | 4.3% | ||||
| IDG China Capital Fund GP III Associates Ltd. | 4.3% | ||||
| Zhou Quan | 4.3% | ||||
| Ho Chi Sing | 4.3% | ||||
|
Pony AI Inc.
13G
PONY · 732908108
|
6.7% |
5/29/2025
Event 12/31/2024
|
|||
| IDG China Venture Capital Fund IV L.P. | 6.7% | ||||
| IDG China IV Investors L.P. | 6.7% | ||||
| IDG China Capital Fund III L.P. | 6.7% | ||||
| IDG China Capital III Investors L.P. | 6.7% | ||||
| IDG China Venture Capital Fund IV Associates L.P. | 6.7% | ||||
| IDG China Venture Capital Fund GP IV Associates Ltd. | 6.7% | ||||
| IDG China Capital Fund III Associates L.P. | 6.7% | ||||
| IDG China Capital Fund GP III Associates Ltd. | 6.7% | ||||
| Zhou Quan | 6.7% | ||||
| Ho Chi Sing | 6.7% | ||||
|
CASI Pharmaceuticals, Inc.
13D/A
Amendment 6
CASIF · G1933S101
|
6.4% |
2/3/2025
Event 12/30/2024
|
|||
| IDG-Accel China Growth Fund III L.P. | 5.9% | ||||
| IDG-Accel China III Investors L.P. | 5.9% | ||||
| IDG-Accel China Growth Fund III Associates L.P. | 5.9% | ||||
| IDG-Accel China Growth Fund GP III Associates Ltd. | 5.9% | ||||
| Ho Chi Sing | 5.9% | ||||
| Quan Zhou | 6.4% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.